Overview
Avi Kenny is an Assistant Professor in the Department of Biostatistics and Bioinformatics at Duke University, with a secondary appointment at the Duke Global Health Institute. He holds a PhD in biostatistics from the University of Washington, where he developed statistical methods for immune correlates analysis of vaccine clinical trial data. Prior to this, he worked for five years in Liberia as the Director of Research, Monitoring, and Evaluation at Last Mile Health. His current research interests include statistical methods to handle treatment effect heterogeneity in cluster randomized trials, survival analysis using machine learning tools, evaluation of global health programs, and data quality assurance in low-resource settings.
Current Appointments & Affiliations
Assistant Professor of Biostatistics & Bioinformatics
·
2024 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Assistant Research Professor of Global Health
·
2024 - Present
Duke Global Health Institute,
University Institutes and Centers
Recent Publications
Reducing Child Mortality in Togo With an Integrated Primary Care Program: A Cluster Randomized Clinical Trial.
Journal Article Pediatrics · December 1, 2025 OBJECTIVE: The objective of this study was to evaluate the effectiveness and implementation of the Integrated Primary Care Program (IPCP) in reducing under-five mortality rate (U5M) in Togo when implemented at scale. METHODS: Using a stepped-wedge cluster ... Full text Link to item CiteInference on Controlled Effects for Assessing Immune Correlates of Protection Based on a Cox Model.
Journal Article Stat Med · December 2025 In vaccine research, it is important to identify biomarkers that can reliably predict vaccine efficacy against a clinical endpoint. Such biomarkers are known as immune correlates of protection (CoP) and can serve as surrogate endpoints in vaccine efficacy ... Full text Link to item CiteImmune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial.
Journal Article iScience · November 21, 2025 In Latin American sites of the ENSEMBLE trial of the Ad26.COV2.S vaccine vs. placebo, binding antibodies and neutralizing antibodies measured 4 weeks post-vaccination (∼peak) against circulating lineages (Ancestral, Gamma, Lambda, Mu, Zeta) were assessed a ... Full text Link to item CiteRecent Grants
Targeted Implementation of Pulmonary Rehabilitation for Post-Tuberculosis Lung Disease
ResearchAdvisor · Awarded by National Institutes of Health · 2025 - 2030A randomized controlled trial of a novel, evidence-based algorithm for managing lower respiratory tract infection in a resource-limited setting
ResearchBiostatistician III · Awarded by National Institute of Allergy and Infectious Diseases · 2022 - 2027View All Grants
Education, Training & Certifications
University of Washington ·
2023
Ph.D.